Fintel reports that on September 14, 2023, Canaccord Genuity maintained coverage of Harpoon Therapeutics (NASDAQ:HARP) with a Buy recommendation.
Analyst Price Forecast Suggests 0.74% Upside
As of August 31, 2023, the average one-year price target for Harpoon Therapeutics is 5.44. The forecasts range from a low of 1.52 to a high of $8.40. The average price target represents an increase of 0.74% from its latest reported closing price of 5.40.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Harpoon Therapeutics is 30MM, a decrease of 34.77%. The projected annual non-GAAP EPS is -1.03.
What is the Fund Sentiment?
There are 62 funds or institutions reporting positions in Harpoon Therapeutics. This is a decrease of 14 owner(s) or 18.42% in the last quarter. Average portfolio weight of all funds dedicated to HARP is 0.05%, an increase of 9.48%. Total shares owned by institutions decreased in the last three months by 4.26% to 17,653K shares. 
The put/call ratio of HARP is 0.00, indicating a bullish outlook.
What are Other Shareholders Doing?
MPM Oncology Impact Management holds 3,197K shares representing 82.45% ownership of the company. No change in the last quarter.
New Leaf Venture Partners, L.L.C. holds 3,157K shares representing 81.42% ownership of the company. No change in the last quarter.
Mpm Asset Management holds 3,131K shares representing 80.77% ownership of the company. No change in the last quarter.
Franklin Resources holds 1,323K shares representing 34.13% ownership of the company. No change in the last quarter.
Artal Group holds 1,000K shares representing 25.79% ownership of the company. No change in the last quarter.
Harpoon Therapeutics Background Information
(This description is provided by the company.)
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
